Vitamin K2 Going Mass Market. The Experts Discuss: Successful Product Launches

Format: External webinar | Document type: Webinar

Kappa Biosciences
The unparalleled bone and heart benefits of vitamin K2 MK-7 have opened doors to mass market consumers. More and more K2 products are being launched, with companies and marketers looking to gain first-mover advantage.Join Kappa Bioscience and a panel of industry experts who will discuss and answer questions about launching successful K2 products.The roundtable discussion and Q&A will cover:K2 science Market opportunity Commercial risksFormulationGalenicsStability and qualityAnalysisK2 is ready for mass markets. Join us to learn how to profit from the enormous potential of vitamin K2 MK-7.


Bjarne Bloch Bjarne Bloch Medical Advisor
Orkla Care A/S

Dr. Juergen Wolf Dr. Juergen Wolf General Manager
K2 MedicalCare GmbH

Egil Greve Egil Greve President & CEO
Kappa Bioscience

Francis Foley Francis Foley President
Xsto Solutions

Jim Bornhold Jim Bornhold Executive VP of Nutraceuticals
Chemroy Canada Inc.

Jörg Büttinghaus Jörg Büttinghaus Vice President Sales & Marketing
Kappa Bioscience

Morgan Laloux Morgan Laloux Business Development Manager Consumer Health & Nutrition

Scott Colbourne Scott Colbourne Business Manager NSW, Food & Pharmaceutical
ALS Pharmaceutical Australia

Virpi Varjonen Virpi Varjonen Strategist
Invenire Market Intelligence Oy

Related resources from Kappa Bioscience & XSTO Solutions

Supplier info centre